The European Commission has approved a chewable version of Pfizer's blockbuster cholesterol drug Lipitor, for use in children over the age of 10.
Pfizer has announced that following this approval, it will apply for a six-month patent extension for Lipitor, which is the best-selling drug in the world.
Both the United States and the European Union offer six-month patent extensions as an incentive for drug companies to conduct safety and effectiveness tests of their products in children, which is not required by law. Based on Pfizer's tests of Lipitor in children, the United States has already granted such an extension and the European Union is expected to follow suit.
Coming soon to Europe: Chewable cholesterol drugs for children (like candy)
No comments:
Post a Comment